Expanding the Histologic Spectrum of Human Papillomavirus (HPV)-Associated Oropharyngeal Carcinoma: A Retrospective Study of 379 Cases Focusing on Classification, Histologic Features, and their Prognostic Significance

拓展人乳头瘤病毒(HPV)相关口咽癌的组织学谱:一项回顾性研究,分析379例病例,重点关注分类、组织学特征及其预后意义

阅读:1

Abstract

BACKGROUND: The WHO classification includes squamous cell carcinoma (SCC) and neuroendocrine carcinoma as two histotypes of HPV-associated oropharyngeal carcinoma (HPV + OPC). Among SCC, the recognized subtypes include non-keratinizing, keratinizing, papillary, adenosquamous, ciliated adenosquamous, lymphoepithelial, spindle cell, and basaloid subtypes. DESIGN: This retrospective study included 379 consecutive cases of HPV+ OPC resected between 2017 and 2024. RESULTS: The morphologies included SCC (83.4%), adenosquamous carcinoma (n=11, 2.9%, including 6 with cilia), combined neuroendocrine carcinoma and SCC (n=3, 0.8%), adenocarcinoma (n=1, 0.3%), and undifferentiated carcinoma (n=1, 0.3%). Among SCC subtypes, the most common was non-keratinizing (n=316), followed by papillary (n=22), lymphoepithelial (n=9), basaloid (matrix-producing, n=9), keratinizing (n=6), and spindle cell (sarcomatoid, n=1). Tumors could display various histologic features, such as papillary architecture (29.2%), lymphoepithelial regions (10.3%), and basaloid (matrix-producing) areas (7.1%). On univariate survival analysis, adverse histologic features included any percentage of glandular differentiation, a basaloid component, extranodal extension (ENE), and low stromal tumor infiltrating lymphocytes (sTIL). Basaloid areas and extranodal extension were independent adverse prognostic factors identified on multivariate survival analysis. CONCLUSION: Herein, we report two histotypes of HPV+ OPC not yet recognized by the WHO classification, being adenocarcinoma and undifferentiated carcinoma. Additionally, multiple adverse histologic features were identified, including basaloid components and ENE as independent prognostic factors. Therefore, recognizing and reporting such features in the pathology report of HPV+ OPC, even when present in minor proportions, is important for risk stratification and clinical management. CLINICAL TRIAL REGISTRATION: Not applicable.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。